BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/8/2024 8:33:17 AM | Browse: 91 | Download: 0
Publication Name World Journal of Clinical Oncology
Manuscript ID 97823
Country United States
Category Oncology
Manuscript Type Case Report
Article Title Pembrolizumab-induced Guillain-Barré syndrome in triple-negative breast cancer: A case report
Manuscript Source Unsolicited Manuscript
All Author List Phani Bhavana Cherukuri, Muhammad Tayyeb, Sai Rakshith Gaddameedi, Doantrang Du and Trishala Meghal
Funding Agency and Grant Number
Corresponding Author Phani Bhavana Cherukuri, MD, Department of Internal Medicine, Monmouth Medical Center, 300 2nd Avenue, Long Branch, NJ 07740, United States. dr.bhavana.cherukuri22@gmail.com
Key Words Pembrolizumab; Guillain-Barré syndrome; Triple-negative breast cancer; Immune-related adverse events; Intravenous immunoglobulin therapy; High-dose steroids; Case report
Core Tip The immune checkpoint inhibitor pembrolizumab can cause rare immune-related adverse events like Guillain-Barré syndrome. This report details a patient with stage IIIB triple-negative breast cancer who developed Guillain-Barré syndrome after pembrolizumab treatment. Initial treatment with intravenous immunoglobulin was insufficient, but a combination of intravenous immunoglobulin and high-dose steroids led to significant improvement. This case highlights the importance of recognizing neurological complications in patients treated with pembrolizumab and emphasizes the need for timely diagnosis and multidisciplinary management of such complications.
Citation <p>Cherukuri PB, Tayyeb M, Gaddameedi SR, Du D, Meghal T. Pembrolizumab-induced Guillain-Barré syndrome in triple-negative breast cancer: A case report. <i>World J Clin Oncol</i> 2025; 16(2): 97823</p>
Received
2024-06-10 03:51
Peer-Review Started
2024-06-10 03:51
To Make the First Decision
Return for Revision
2024-09-17 02:58
Revised
2024-10-21 01:13
Second Decision
2024-11-08 02:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2024-11-08 08:33
Articles in Press
2024-11-08 08:33
Publication Fee Transferred
2024-10-25 14:55
Edit the Manuscript by Language Editor
Typeset the Manuscript
2024-11-25 10:05
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com